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Open access undBackground and purpose: For focal boosting of prostate tumors, three questions are important regarding
the use of hormonal therapy. Does prolonged hormonal treatment affect the conspicuity of tumor tissue
on diffusion weighted imaging (DWI) and dynamic contrast-enhanced (DCE-MRI) images? Is tumor delin-
eation possible in patients using hormonal treatment? Can we identify speciﬁc imaging thresholds for
tumor delineation in patients after prolonged androgen deprivation?
Materials and methods: Ninety-six patients were included. Using multivariate linear regression analyses,
we investigated if DWI and DCE-MRI parameter maps are different in patients receiving hormonal treat-
ment for 0–3 or >3 months. Furthermore, logistic regression was performed to obtain speciﬁc imaging
thresholds for tumor tissue for the two patient groups.
Results: We found a signiﬁcantly higher diffusion and lower perfusion of tumor tissue in the >3 months
hormonal treatment group compared to the 0–3 group. This resulted in lower tumor conspicuity. Never-
theless, in 18/21 of the patients in the >3 months treatment group, a suspicious lesion could be deﬁned
based on the MR images. Based on logistic regression, different imaging thresholds should be set for
tumor detection in the two treatment groups.
Conclusions: Prolonged androgen deprivation decreases tumor conspicuity. Different imaging thresholds
need to be set to delineate tumor in patients who have had prolonged hormonal treatment.
 2011 Elsevier Ireland Ltd. Open access under the Elsevier OA license.
Radiotherapy and Oncology 103 (2012) 233–238As evidence is emerging that local recurrences of prostate tu-
mors are often seen at the original tumor location [1,2], an addi-
tional boost dose to this tumor could improve the tumor control
probability. By limiting the boost to the visible tumor, the toxicity
to the organs at risk may be kept at a minimal level [3–6].
Magnetic resonance imaging (MRI) techniques such as diffusion
weighted imaging (DWI) and dynamic contrast enhanced (DCE)
MRI have high sensitivity and speciﬁcity for tumor detection inside
the prostate [7–13]. Using DWI, the mobility of water molecules is
measured. Several studies have shown that tumor tissue is associ-
ated with reduced water diffusion [7–11]. This is attributed to a
reduction of the extracellular volume in tumors.
Using DCE-MRI, tissue perfusion is measured. This technique
can be used for the detection of tumors in the prostate, as tumors
tend to contain a higher density of leaky blood vessels [12,14–16].
Since both DWI and DCE-MRI have a high sensitivity and speci-
ﬁcity for tumor detection, potentially they are good candidates to
guide tumor delineation in the prostate [17]. However, the rangeical Center Utrecht, Heidel
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er the Elsevier OA license.of values of the functional parameters derived from DWI and DCE-
MRI is quite large and overlaps partly for tumor and healthy tissues.
In an earlier study, we addressed the problem of how to deal
with conﬂicting information from DWI and DCE-MRI. Prostate vox-
els, which appear suspicious on both imaging modalities could be
treated as GTV, whereas in case only one of the two modalities
indicates a voxel as suspicious, the region could be considered a
‘high-risk CTV’ [18].
Furthermore, approaches were proposed to deal with uncer-
tainties within the parameter maps [19]. A more robust approach
to tumor delineation would use thresholds for the functional
parameter maps. However, the large range of values observed, re-
sults in a gradual change in tumor probability, rather than a sharp
threshold. Understanding the causes of the variation in parameter
values, we may reﬁne this approach and develop threshold values
for speciﬁc groups of patients.
Hormonalwithdrawal is oneof the factors inﬂuencingprostate tu-
mor tissue. Previous studies have shown that these changes affect the
parametersmeasuredwith DCE-MRI [20,21]. Furthermore, androgen
withdrawal triggers the apoptotic pathway in androgen-dependent
prostate cancer cells [22]. Since, the apparent diffusion coefﬁcient
(ADC) measured with DWI is correlated with cell density [23–25],
234 Hormonal treatment and prostate cancer imagingwe must take into consideration that androgen deprivation also af-
fects the ADC.
For radiotherapy treatment planning three questions are impor-
tant regarding patients using this hormonal treatment. First, does
prolonged hormonal treatment affect the conspicuity of tumor tis-
sue (tumor signal relative to background) on DWI and DCE-MRI
images? Is tumor delineation possible in patients using hormonal
treatment? And can we identify speciﬁc imaging thresholds for tu-
mor delineation in patients after prolonged androgen deprivation?
In this study we address these questions by retrospectively inves-
tigating the DWI and DCE-MRI data from patients that have under-
gone androgen deprivation therapy for different periods of time.
Methods and materials
Patients
Ninety-six patients with biopsy proven prostate cancer, sched-
uled for intensity-modulated radiotherapy (IMRT) and 125-I brachy
therapy were included. Patient characteristics are summarized in
Table 1. All patients were treated between January 2008 and July
2010 and were candidates for hormonal treatment. However, the
periods of treatment time at the time of the MR exam differed be-
tween patients. The patients were divided in two groups based on
the duration of the hormonal treatment: 0–3 and >3 months.
Patients scheduled for brachy therapy are treated with hormonal
therapy, when the prostate is considered too large for proper dose
coverage with the 125-I seeds. In our institute the standard hor-
monal treatment prior to brachytherapy takes 6 months. In IMRT
patients hormonal treatment is prescribed to improve treatment
outcome [26]. The distribution of brachy therapy and IMRT patients
over the two groups is shown in Table 1.Imaging
On all patients a T2 weighted (T2w), balanced turbo ﬁeld echo
(bTFE), DWI and DCE-MRI examwere performed using a 3 T Philips
Achieva MR scanner. A 6-element phased array coil (sense cardiac)
was used as receive coil during the scans. We decided not to use an
endorectal coil to prevent deformations of the prostate, that compli-
cate the radiotherapy treatment planning. T2w images were
acquired with a fast spin–echo sequence, TR/TE = 8396/120 ms,Table 1
Patient characteristics at time of MR scans.
Number of patients
0–3 months
hormonal
therapy
>3 months
hormonal
therapy
Total 75 21
Primary tumor stage
Tx 1 (1%) 0 (0%)
T1 6 (8%) 5 (24%)
T2 12 (16%) 6 (29%)
T3 54 (72%) 10 (48%)
T4 2 (3%) 0 (0%)
Gleason score
5 1 (1%) 0 (0%)
6 5 (7%) 9 (43%)
7 23 (31%) 6 (29%)
8 33 (44%) 3 (14%)
9 11 (15%) 2 (10%)
10 2 (3%) 1 (5%)
Pre-treatment PSA level (ng/ml) 15.1 (3.3–77) 11.4 (3.5–50)
Age (years) 68 (47–83) 69 (60–79)
IMRT 68 (91%) 9 (43%)
125-I 7 (9%) 12 (57%)echo train length 13, acquisition matrix 256  256, ﬁeld of view
(FOV) = 20 cm, slice thickness 3 mm, intersection gap 1 mm. bTFE:
TR/TE = 2.85/1.43 ms, echo train length = 40, acquisition matrix
192  249, FOV = 25 cm, slice thickness = 2 mm.
DWI scans were performed using a multislice single shot
spin–echo planar imaging (SE-EPI) sequence (FOV = 38 cm, slice
thickness = 3 mm, EPI-factor = 47, intersection gap = 1 mm, TR/
TE = 5000/54 ms, acquisition matrix = 152  107, nine averages,
sense factor = 2 in anterior–posterior direction, phase encoding
direction = posterior–anterior). b values 300, 500 and 1000 s/mm2
were used to calculate the apparent diffusion coefﬁcient (ADC).
TheDCE-MRIprotocolusedconsistedofa3Dspoiledgradientecho
sequence (20 transverse partitions, 2.5 mm section thickness, TR/
TE = 4/1 ms, ﬂip angle 8, FOV = 40 cm, acquisition matrix = 160
 160). Scans were repeated 120 times at 2.4 s interval. A concentra-
tion of 0.1 ml/kg ofGadubutrol (1.0 M) (Gadovist, ScheringAG, Berlin,
Germany) contrast was injected with 2 ml/s, followed by a saline
ﬂush. Concentration of the contrast agent was calculated from the
MR signal usingpreceding small ﬂip angle scanswith threeﬂip angles
(6, 16 and 32, TR/TE = 50/1.1 ms). Before applying a tracer kinetics
model, a moving average ﬁlter of 3  3  3 voxels in the x, y and z
directionwasused to increase the signal-to-noise ratio. Then, for each
voxel the generalized kinetic model [27] was ﬁtted to the measured
concentration time curves, using the linear least-squared method
published byMurase [28]. This yielded 3Dmaps of the volume trans-
fer constantKtrans. Due to the extent of themeasurement errors on the
patient speciﬁc input functions, a generic patient averaged arterial in-
put function (AIF)wasused for all patients. A similar approach isoften
used to circumvent problems with AIF measurements [29–32].Analysis
In all patients the prostate and the peripheral zone (PZ) were
delineated using the T2w image and bTFE scan. The PZ was ana-
lyzed separately to be insensitive to BPH. To quantitatively study
the effect of androgen deprivation on MR parameter values inside
the tumor we calculated for each patient the lowest mean ADC and
the highest mean Ktrans in a 5  5  5 mm3 kernel inside both the
prostate and PZ. These values were assumed to be representative
for ADC and Ktrans values in tumor tissue. At the same time the
median ADC and the median Ktrans inside the prostate and PZ were
assumed to be representative for healthy tissue (Fig. 1).
Weused linear regression analysis to study the effect of the dura-
tion of the hormonal treatment prior to the MR scan on the lowest
mean ADC, highest mean Ktrans and median ADC and Ktrans values.
IMRT and 125-I brachy therapy patients are scheduled for hormonal
treatment for different reasons. Since IMRT and I-125 brachy ther-
apy patients are not equally distributed in the two hormonal treat-
ment groups, the two groups may not be comparable. For this
reason we adjusted for the effect of potential confounding factors.
The following factors, which might be associated with both the
duration of the hormonal treatment and the MR parameters, were
considered as confounders: patient age, PSA, Gleason score (GS)
(in three categories: GS < 7, GS = 7, GS > 7), T stage (in three catego-
ries T stage < 2, T stage = 2, T stage > 2), size of prostate and PZ.
First,we assessed the crude relation between the durationof hor-
monal treatment and MR parameters. Second, we added all
potential confounders and removed themsingly usingmanual back-
ward elimination. A factor was considered as a relevant confounder
when it changed the regression coefﬁcient by more than 10%.
To identify if we can develop threshold values for speciﬁc
groups of patients, we ﬁtted a logistic regression model through
our ADC and Ktrans data for both the 0–3 and >3 months hormonal
treatment group. To this end we assumed that the lowest mean
ADC and highest mean Ktrans values in a 5  5  5 mm3 adjacent
kernel are representative for tumor values, whereas median ADC
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Similar as done by Korporaal et al. [19] we looked for thresholds
for the ADC and Ktrans for which a tumor probability of 95% was
predicted according to the logistic regression model. Voxels inside
the prostate exceeding this threshold could be considered as gross
tumor volume [19]. Threshold values were established for both the
0–3 and >3 months hormonal treatment group.
For statistical analyses we used SPSS 16.0.Results
The duration of hormonal treatment was correlated with both
the mean lowest ADC and mean highest Ktrans (pearson correla-
tion = 0.32 and 0.35, respectively, with p values 0.002 and
0.001). Increasing ADC values and decreasing Ktrans values were
found for increasing treatment times. Nevertheless, a large spread
in the data can be appreciated (Fig. 2a and b).
The mean lowest ADC and mean highest Ktrans values for the dif-
ferent hormonal treatment duration periods as well as the regres-
sion coefﬁcients (b) and the corresponding p values are given in
Table 2. In assessing the relation between the functional MR values
between the two hormonal therapy groups, GS > 7 was identiﬁed
as a confounding factor in the relation between duration of hor-
monal treatment and the mean lowest ADC values. GS > 7 was
associated with lower values of tumor ADC. The difference in mean
lowest ADC values between the two hormonal treatment groupsFig. 1. To be insensitive to interobserver variations, in this paper, we assumed that medi
tissue. The lowest mean ADC and highest mean Ktrans in a 5  5  5 mm3 kernel were as
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Fig. 2. The correlation between the duration of hormonal therapy at the time of the Mcan be partly described by GS. By taking the effect of GS into
account we found slightly smaller associations between duration
of hormonal treatment and mean lowest ADC values (Table 2).
No confounding factors could be identiﬁed for the relation be-
tween the duration of hormonal treatment and the Ktrans values.
A signiﬁcant differencewas found between themean lowest ADC
and the mean highest Ktrans between the 0–3 and >3 months hor-
monal therapy groups. In the total prostate the mean lowest ADC
is on average 1.2  104 mm2/s higher and the mean highest Ktrans
0.14 min1 lower in the >3 months treatment group. At the same
time, the median ADC, assumed to be representative for healthy
tissue, was not affected by the duration of the hormonal treatment
(p = 0.97 and p = 0.68 for the prostate and PZ, respectively). The
median Ktrans values were only slightly affected by the duration of
the hormonal treatment (b = 0.03, p = 0.07 and b = 0.03,
p = 0.045 for both the prostate and PZ, respectively, Table 2). Since
tumor tissue ismuchmore affected by the hormonal treatment than
healthy tissue, increasing hormonal treatment times decrease the
conspicuity of suspicious regions inside the prostate.
Even though the conspicuity of suspicious volumes is smaller in
patients who had used hormonal treatment for a longer period of
time, in 18/21 of the patients, who had used hormonal treatment
longer than 3 months at the time of the MR exam, a suspicious vol-
ume could be deﬁned based on qualitative assessment of the ADC
and Ktrans images. In Fig. 3, the ADC and Ktrans maps of two typical
patients are shown. Patient 1 (1a and 1b) had used hormonal treat-
ment less than 3 months at the time of the MR exam. Patient 2an values of ADC and Ktrans inside the prostate and PZ are representative for healthy
sumed to be representative for tumor tissue.
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R scan and the mean lowest ADC and mean highest Ktrans in the peripheral zone.
Table 2
ADC and Ktrans values for patients using hormonal treatment 0–3 months and >3 months at the time the MR exam was performed.
n Mean Standard deviation b p b adjusted confounders p
Values for tumor tissue
Mean lowest ADCprostatea (mm2/s)
0–3 months 75 4.7  104 1.7  104 Reference
>3 months 21 6.0  104 1.9  104 1.3  104 0.001 1.2  104a 0.003
Mean lowest ADCPZa (mm2/s)
0–3 months 75 5.4  104 1.4  104 Reference
>3 months 21 7.0  104 1.5  104 1.5  104 0.001 1.3  104a 0.008
Mean highest Ktransprostate (min
1)
0–3 months 75 0.46 0.21 Reference
>3 months 21 0.32 0.13 0.14 0.009
Mean highest KtransPZ (min
1)
0–3 months 75 0.35 0.16 Reference
>3 months 21 0.22 0.10 0.13 0.001
Values for healthy tissue
Median ADCprostate (mm2/s)
0–3 months 75 11  104 1.5  104 Reference
>3 months 21 11  104 1.4  104 0.02  104 0.97
Median ADCPZ (mm2/s)
0–3 months 75 11  104 1.8  104 Reference
>3 months 21 11  104 1.5  104 0.2  104 0.68
Median Ktransprostate (min
1)
0–3 months 75 0.16 0.06 Reference
>3 months 21 0.13 0.06 0.03 0.07
Median KtransPZ (min
1)
0–3 months 75 0.15 0.06 Reference
>3 months 21 0.12 0.05 0.03 0.045
a Adjusted for Gleason score.
236 Hormonal treatment and prostate cancer imaging(2a, 2b, 2c and 2d) had used the hormonal treatment for more than
3 months at the time of the MR exam. In both patients a suspicious
volume is found on the right side of the PZ. However, the conspicu-
ity of the suspicious lesion is considerably larger in patient 1.
Adjustment of the window/level settings nevertheless allows iden-
tiﬁcation of the suspicious lesion in patient 2 (2c and 2d). This sug-
gests that different threshold values need to be chosen to deﬁne
tumor tissue after prolonged hormonal treatment.
To assess imaging threshold values for ADC and Ktrans maps, we
performed logistic regression. Before calculating the tumor proba-
bility functions based on ADC values, the mean lowest ADC values
were adjusted for GS. The duration of hormonal therapy affects the
tumor probability functions based on Ktrans and ADC values in the
PZ (Fig. 4a and b). Based on Fig. 4, for a tumor probability of 95%,
ADC thresholds should be set at 7.8  104 mm2/s and 6.7  104
for the patients who used the hormonal treatment longer than
3 months and patients who used the treatment 0–3 months,
respectively. For the same tumor probability the Ktrans maps should
be thresholded at 0.25 or 0.35 min1 for the patients who used the
hormonal treatment longer than 3 months and patients who used
the treatment 0–3 months, respectively (Fig. 4).
Discussion
In this study, we retrospectively investigated the relation
between the duration of androgen deprivation and DWI and
DCE-MRI parameters. We found that tumor ADC values are associ-
ated with prolonged use of androgen deprivation. Tumor ADC val-
ues are considerably larger for longer hormonal treatment periods.
After adjusting for GS, the mean lowest ADC in the PZ is 1.3  104
higher in the >3 months group, than in the 0–3 months group. ADC
is correlated with cell density [23–25]. Since, androgen withdrawal
triggers the apoptotic pathway in androgen-dependent prostate
cancer cells [22], this may explain the higher ADC values in pa-
tients with longer androgen deprivation periods.We showed a decrease in Ktrans values for increasing duration of
the androgen deprivation treatment. On average the mean highest
Ktrans is 0.13 min1 lower in the PZ in the >3 months hormonal
therapy group, compared to the 0–3 months group. This is consid-
erable given the spread in the data and the difference between
healthy and tumor tissue. Since Ktrans is associated with the num-
ber of leaky blood vessels, the decreased Ktrans values after hor-
monal treatment suggest a decrease in tumor microvasculature.
This result is in agreement with what was found by Alonzi et al.
[20].
The duration of hormonal therapy did not have a large effect on
healthy tissue. Therefore, the conspicuity of tumor tissue is smaller
in patients that had used hormonal treatment for a longer period.
Nevertheless, in 18/21 patients it was still possible to deﬁne a sus-
picious region inside the PZ by qualitative assessment of the
images.
Since the conspicuity of tumor tissue is smaller in patients with
prolonged hormonal treatment use, ideally patients would start
this treatment after the MR exam. However, many of the patients
coming to a radiotherapy department are already using androgen
deprivation. Therefore, when choosing a quantitative approach
for tumor delineation it is of high importance to incorporate the
knowledge on the effect of the duration of hormonal treatment
on the MR scans. In this way, patient group speciﬁc imaging
thresholds can be deﬁned (Fig. 4a and b). However, the duration
of hormonal treatment only partly explains the variation we ﬁnd
in ADC and Ktrans values for different patients. The causes of this
variation in ADC and Ktrans values between patients need to be
studied further. Understanding the causes of variation could in-
crease the voxel based sensitivity and speciﬁcity of DWI and
DCE-MRI by the deﬁnition of more speciﬁc thresholds for the indi-
vidual patient.
IMRT and 125-I brachy patients are scheduled for hormonal
treatment for different reasons. Patients scheduled for brachy
therapy are treated with hormonal therapy, when the prostate is
Fig. 3. ADC and Ktrans maps of two patients. The black arrows point at the regions which are suspicious for tumor. The white arrows point at regions that probably contain
BPH. Patient 1 (1a and 1b) had used hormonal treatment less than 3 months at the time of the MR exam. Patient 2 (2a, 2b, 2c and 2d) had used the hormonal treatment for
more than 3 months at the time of the MR exam. In both patients a suspicious volume is found on the right side of the PZ. However, the conspicuity of the suspicious lesion is
larger for patient 1. Adjustment of the window/level settings improves the visibility of the suspicious lesion in patient 2 (2c and 2d).
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Fig. 4. Tumor probability for different duration of hormonal treatment. The gray line represents the tumor probability function for patients who used hormonal treatment
0–3 months at the time of the MR exam. The black line represents the tumor probability function for patients using the hormonal treatment longer than 3 months at the time
of the MR exam. In this situation, when one decides to boost only voxels with a tumor probability larger than 95% the Ktrans maps should be thresholded at 0.25 or 0.35 min1
for the patients who used the hormonal treatment longer than 3 months and patients who used the treatment 0–3 months, respectively. For a the same tumor probability
ADC maps should be thresholded at 6.7  104 and 7.8  104 mm2/s for the patients who used the hormonal treatment longer than 3 months and patients who used the
treatment 0–3 months, respectively.
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In our institute the standard hormonal treatment prior to brachy-
therapy takes 6 months. In IMRT patients hormonal treatment is
prescribed to improve treatment outcome [26]. Usually, the radio-
therapy treatment starts relatively shortly after the start of hor-
monal treatment in these patients. As a result the IMRT and 125-Ibrachy patients are not equally distributed over the two groups.
Therefore, we investigated if we could identify confounding factors
for the duration of hormonal treatment and ADC and Ktrans values.
GS > 7 was identiﬁed as a confounding factor in the relation be-
tween duration of hormonal treatment and the mean lowest ADC.
So, part of the difference in ADC values in the two hormonal
238 Hormonal treatment and prostate cancer imagingtreatment groups can be explained by the larger number of patients
with high GS in the 0–3 months hormonal treatment group (Table
2). The found effect of GS on ADC is in agreementwith the literature.
Lower ADC values have been reported for higher GS [33–35].
This study has several limitations. First, we used the mean low-
est ADC and the mean highest Ktrans in a 5  5  5 mm3 kernel in-
side the prostate and PZ as a measure for tumor tissue. This
assumption may not be valid in all patients. However, since path-
ological validation is not possible in these patients, we prefer this
measure because of its insensitivity to interobserver variations.
We decided to choose a small kernel, to increase the chance that
all voxels inside the kernel contain tumor tissue. In this way we
only take the lowest ADC and the highest Ktrans in a tumor into ac-
count. For this reason the reported tumor ADC values are lower
than the average tumor ADC, whereas the reported Ktrans values
are higher than the average tumor Ktrans.
Furthermore, we retrospectively included patients with differ-
ent start dates of the hormonal treatment to study the effect of
duration of androgen deprivation on MR parameters rather than
performing a longitudinal study. In this way it was possible to in-
clude a large patient number. However, this study approach may
dilute the effect of duration of hormonal treatment on ADC and
Ktrans. Furthermore, it is not possible to model the effect of hor-
monal treatment on the individual patient.
Despite these limitations, we could answer the relevant ques-
tions regarding the use of hormonal treatment in radiotherapy pa-
tients. Although, hormonal treatment affects tumor conspicuity in
the prostate, the majority of hormonal treatment patients can be
treated with a focal boost to a suspicious region inside the prostate.
However, different imaging thresholds should be chosen depending
on the duration of the hormonal treatment. Using this kind of clin-
ical information for tumor delineation in the prostate, radiotherapy
treatment could be further optimized for each individual patient.
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